Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

Robert C Stein; Andrea Marshall; Andreas Makris; Luke Hughes-Davies; Iain R MacPherson; Carmel Conefrey; Leila Rooshenas; Sarah E Pinder; Abeer M Shaaban; Bjørn Naume; David A Cameron; Daniel W Rea; Helena M Earl; Christopher J Poole; Peter S Hall; Georgina Dotchin; Stuart A McIntosh; Victoria Harmer; Adrienne Morgan; Bethany Shinkins; Nigel Stallard; Christopher McCabe; Jenny L Donovan; John MS Bartlett; Janet A Dunn

doi:10.1158/1538-7445.SABCS19-OT3-17-01

Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

Robert C Stein, Andrea Marshall, Andreas Makris, Luke Hughes-Davies, Iain R MacPherson, Carmel Conefrey, Leila Rooshenas, Sarah E Pinder, Abeer M Shaaban, Bjørn Naume, David A Cameron, Daniel W Rea, Helena M Earl, Christopher J Poole, Peter S Hall, Georgina Dotchin, Stuart A McIntosh, Victoria Harmer, Adrienne Morgan, Bethany ShinkinsNigel Stallard, Christopher McCabe, Jenny L Donovan, John MS Bartlett, Janet A Dunn

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	OT3-17-01
Journal	Cancer Res
Volume	80
Issue number	4 Supplement
DOIs	https://doi.org/10.1158/1538-7445.SABCS19-OT3-17-01
Publication status	Published - 14 Feb 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1538-7445.SABCS19-OT3-17-01Licence: Unspecified

OPTIMA Trial Management Group (External organisation)
McIntosh, S. (Member)
2017 → …
Activity: Other activity types › Other

Cite this

Stein, R. C., Marshall, A., Makris, A., Hughes-Davies, L., MacPherson, I. R., Conefrey, C., Rooshenas, L., Pinder, S. E., Shaaban, A. M., Naume, B., Cameron, D. A., Rea, D. W., Earl, H. M., Poole, C. J., Hall, P. S., Dotchin, G., McIntosh, S. A., Harmer, V., Morgan, A., ... Dunn, J. A. (2020). Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer. Cancer Res, 80(4 Supplement), Article OT3-17-01. https://doi.org/10.1158/1538-7445.SABCS19-OT3-17-01

@article{8665a79b66114c8998213caa1fc3b3a6,

title = "Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer",

author = "Stein, {Robert C} and Andrea Marshall and Andreas Makris and Luke Hughes-Davies and MacPherson, {Iain R} and Carmel Conefrey and Leila Rooshenas and Pinder, {Sarah E} and Shaaban, {Abeer M} and Bj{\o}rn Naume and Cameron, {David A} and Rea, {Daniel W} and Earl, {Helena M} and Poole, {Christopher J} and Hall, {Peter S} and Georgina Dotchin and McIntosh, {Stuart A} and Victoria Harmer and Adrienne Morgan and Bethany Shinkins and Nigel Stallard and Christopher McCabe and Donovan, {Jenny L} and Bartlett, {John MS} and Dunn, {Janet A}",

year = "2020",

month = feb,

day = "14",

doi = "10.1158/1538-7445.SABCS19-OT3-17-01",

language = "English",

volume = "80",

journal = "Cancer Res",

issn = "1538-7445",

publisher = "American Association for Cancer Research Inc.",

number = "4 Supplement",

}

Stein, RC, Marshall, A, Makris, A, Hughes-Davies, L, MacPherson, IR, Conefrey, C, Rooshenas, L, Pinder, SE, Shaaban, AM, Naume, B, Cameron, DA, Rea, DW, Earl, HM, Poole, CJ, Hall, PS, Dotchin, G, McIntosh, SA, Harmer, V, Morgan, A, Shinkins, B, Stallard, N, McCabe, C, Donovan, JL, Bartlett, JMS & Dunn, JA 2020, 'Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer', Cancer Res, vol. 80, no. 4 Supplement, OT3-17-01. https://doi.org/10.1158/1538-7445.SABCS19-OT3-17-01

Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer. / Stein, Robert C; Marshall, Andrea; Makris, Andreas et al.
In: Cancer Res, Vol. 80, No. 4 Supplement, OT3-17-01, 14.02.2020.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

AU - Stein, Robert C

AU - Marshall, Andrea

AU - Makris, Andreas

AU - Hughes-Davies, Luke

AU - MacPherson, Iain R

AU - Conefrey, Carmel

AU - Rooshenas, Leila

AU - Pinder, Sarah E

AU - Shaaban, Abeer M

AU - Naume, Bjørn

AU - Cameron, David A

AU - Rea, Daniel W

AU - Earl, Helena M

AU - Poole, Christopher J

AU - Hall, Peter S

AU - Dotchin, Georgina

AU - McIntosh, Stuart A

AU - Harmer, Victoria

AU - Morgan, Adrienne

AU - Shinkins, Bethany

AU - Stallard, Nigel

AU - McCabe, Christopher

AU - Donovan, Jenny L

AU - Bartlett, John MS

AU - Dunn, Janet A

PY - 2020/2/14

Y1 - 2020/2/14

U2 - 10.1158/1538-7445.SABCS19-OT3-17-01

DO - 10.1158/1538-7445.SABCS19-OT3-17-01

M3 - Meeting abstract

SN - 1538-7445

VL - 80

JO - Cancer Res

JF - Cancer Res

IS - 4 Supplement

M1 - OT3-17-01

ER -

Stein RC, Marshall A, Makris A, Hughes-Davies L, MacPherson IR, Conefrey C et al. Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer. Cancer Res. 2020 Feb 14;80(4 Supplement):OT3-17-01. doi: 10.1158/1538-7445.SABCS19-OT3-17-01

Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

UN SDGs

Access to Document

Activities

OPTIMA Trial Management Group (External organisation)

Cite this